Free tool
FAERS Monitor: Vizamyl
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203137 or its brand name (Vizamyl, Flutemetamol F-18). Reports on generic versions are filed under their own applications.
Reports
520
Serious
166
32% of reports
Hospitalization
30
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- flushing265
- dyspnoea140
- back pain120
- dizziness91
- nausea87
- chest discomfort62
- headache51
- chest pain46
- cough39
- erythema39
- feeling hot37
- hot flush29
- hyperhidrosis28
- blood pressure increased27
- muscle spasms27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 13 |
| 2020 | 7 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 76 |
| 2025 | 199 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flushingSignal | 265 | 105.7 | 97.1 | 27,442 |
| chest discomfortSignal | 62 | 24.5 | 19.4 | 1,380 |
| feeling hotSignal | 37 | 24.4 | 17.9 | 810 |
| back painSignal | 120 | 20.9 | 17.9 | 2,278 |
| hot flushSignal | 29 | 15.6 | 10.9 | 382 |
| chest painSignal | 46 | 10.0 | 7.6 | 369 |
| dyspnoeaSignal | 140 | 10.0 | 8.7 | 1,157 |
| hyperhidrosisSignal | 28 | 8.8 | 6.1 | 187 |
| erythemaSignal | 39 | 7.7 | 5.7 | 222 |
| dizzinessSignal | 91 | 7.4 | 6.1 | 508 |
| blood pressure increasedSignal | 27 | 7.1 | 4.9 | 138 |
| muscle spasmsSignal | 27 | 6.0 | 4.1 | 107 |
| coughSignal | 39 | 5.6 | 4.2 | 146 |
| nauseaSignal | 87 | 4.4 | 3.7 | 238 |
| headacheSignal | 51 | 3.3 | 2.5 | 81 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.